A Phase 2 interventional study of BGJ398 in Recurrent Glioblastoma or Other Glioma Subtypes, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-04.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Glioblastoma by Novartis — none open to participants now, 4 under way, none of them phase 3. Glioblastoma · Novartis.
Among the 22 studies in Glioblastoma by Novartis, this one is the 18th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 2, and was the 13th registered.
2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.
Browse Glioblastoma studies →None of the 22 studies in Glioblastoma by Novartis is open now. The open studies under Glioblastoma, anywhere →
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 10 · Phase 3 1 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 52 across the 22 interventional studies. Of the 18 that completed or were terminated, 8 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
1 of the studies in Glioblastoma by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05739942Novartis PharmaceuticalsDose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma | 2027-08-10 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Glioblastoma by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to adult patients with histologically confirmed GBM and/or other glioma subtypes with FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3.
Patients were enrolled in two groups. Group 1 enrolled patients who are not candidates for surgery. Group 2 was planned to enroll patients who are surgical candidates. Patients from both groups were evaluated for tumor response and progression by MRI every 8 weeks until disease progression or discontinuation from study using RANO criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To estimate anti-tumor efficacy of BGJ398
Drug: BGJ398
Capsule for oral use.
Progression Free Survival
To assess the anti-tumor activity of BGJ398 for patients with GBM and/or other glioma subtypes that harbor FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3 based on PFS6 (PFS rate at 6 months as defined by RANO criteria as assessed by the investigator)
Time frame: 6 months
Overall Response Rate
To further assess the anti-tumor activity of BGJ398 for patients with GBM with an amplification, translocation, or activating mutation in FGFR1,2,3 or 4, based on Objective Response Rate (ORR - patients with measurable disease - as defined by RANO criteria as assessed by the investigator
Time frame: 5 years
Overall Survival
To further assess the anti-tumor activity of BGJ398 for patients with GBM and/or other glioma subtypes that harbor FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 and 3 based on Overall Survival
Time frame: 5 years
Safety and Tolerability
Safety: type, frequency, and severity of AEs and SAEs; Tolerability: dose interruptions, reductions and dose intensity, and evaluations of laboratory values
Time frame: 5 years
All 26 patients included were enrolled in the non-Surgical group, and were treated with BGJ398 125 mg once daily in 28-day cycles, on a 3 weeks on/1 week off schedule (dosing days 1 to 21 of every 28-day cycle). No patients were enrolled in the surgical group.
| Milestone | BGJ398X |
|---|---|
| Started | 26 |
| Completed | 1 |
| Not completed | 25 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Death | 23 |
| Withdrew: Physician decision | 1 |
To assess the anti-tumor activity of BGJ398 for patients with GBM and/or other glioma subtypes that harbor FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3 based on PFS6 (PFS rate at 6 months as defined by RANO criteria as assessed by the investigator)
| months | BGJ398X |
|---|---|
| Progression Free Survival | 1.7 (1.05 to 2.80) |
To further assess the anti-tumor activity of BGJ398 for patients with GBM with an amplification, translocation, or activating mutation in FGFR1,2,3 or 4, based on Objective Response Rate (ORR - patients with measurable disease - as defined by RANO criteria as assessed by the investigator
| Participants | BGJ398X |
|---|---|
| partial response | 2 |
| stable disease | 7 |
| progressive disease | 13 |
| unknown | 3 |
| missing | 1 |
To further assess the anti-tumor activity of BGJ398 for patients with GBM and/or other glioma subtypes that harbor FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 and 3 based on Overall Survival
| months | BGJ398X |
|---|---|
| Overall Survival | 6.74 (4.17 to 11.73) |
Safety: type, frequency, and severity of AEs and SAEs; Tolerability: dose interruptions, reductions and dose intensity, and evaluations of laboratory values
| Participants | BGJ398X |
|---|---|
| participants with dose interruptions | 13 |
| participants with dose reductions | 4 |
Collected over All AEs reported in this record are treatment emergent AEs, collected from date of First Patient First Treatment until the completion of the safety follow-up ( 30 days after the Last Patient Last Treatment ) up to approximately 5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Non Surg BGJ398 125 mg | 3/26 (11.5%) | 9/26 (34.6%) | 26/26 (100%) |
| Event | Non Surg BGJ398 125 mg |
|---|---|
| Neurological decompensationNervous system disorders | 2/26 |
| CataractEye disorders | 1/26 |
| VomitingGastrointestinal disorders | 1/26 |
| General physical health deteriorationGeneral disorders | 1/26 |
| Decreased appetiteMetabolism and nutrition disorders | 1/26 |
| DehydrationMetabolism and nutrition disorders | 1/26 |
| HyperphosphataemiaMetabolism and nutrition disorders | 1/26 |
| AtaxiaNervous system disorders | 1/26 |
| EpilepsyNervous system disorders | 1/26 |
| HemiparesisNervous system disorders | 1/26 |
| Event | Non Surg BGJ398 125 mg |
|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 20/26 |
| FatigueGeneral disorders | 9/26 |
| DiarrhoeaGastrointestinal disorders | 8/26 |
| ConstipationGastrointestinal disorders | 7/26 |
| DyspepsiaGastrointestinal disorders | 7/26 |
| HeadacheNervous system disorders | 6/26 |
| StomatitisGastrointestinal disorders | 5/26 |
| Decreased appetiteMetabolism and nutrition disorders | 4/26 |
| HyperlipasaemiaMetabolism and nutrition disorders | 4/26 |
| HypophosphataemiaMetabolism and nutrition disorders | 4/26 |
| Age, Continuous(years) | BGJ398X |
|---|---|
| Mean | 53.7 ± 13.59 |
| Sex: Female, Male(Participants) | BGJ398X |
|---|---|
| Female | 10 |
| Male | 16 |
| Race/Ethnicity, Customized(Participants) | BGJ398X |
|---|---|
| caucasian | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2013 to primary completion in Oct 2018, 57 months.
Results were first posted in Dec 2019, 1 year 2 months after primary completion. A results delay was requested in Sep 2018.
Of 51 industry-sponsored phase 2 interventional studies under Glioblastoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 58. This study's 57 months is above that.
Counting every sponsor, half of 249 studies reached it within 56 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib